Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Keytruda (Pembrolizumab) | Lung Cancer

FDA Approves Adjuvant Pembrolizumab for Non-Small Cell Lung Cancer Treatment

Posted on January 30, 2023
Post Views: 271

Keytruda (Pembrolizumab) | Lung CancerThe US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the results from the phase 3, multicenter, randomized and placebo-controlled KEYNOTE-091 trial.

In the trial, 1177 patients who had undergone resection with or without standard adjuvant chemotherapy were randomized into two treatment arms. One received 200mg intravenous pembrolizumab every three weeks for up to a year and other were treated with placebo every three weeks for up to a year. Patients in treatment arm 1 who received adjuvant chemotherapy had a median DFS was 58.7 months while patients in placebo arm receiving adjuvant chemotherapy had a median DFS of 34.9 months.

The adverse reactions observed in KEYNOTE-09 were gradually similar to those occurring in patients with NSCLC receiving KEYTRUDA as a single agent. The recommended dose of pembrolizumab is 200 mg every three weeks or 400 mg every six weeks until recurrence of disease or up to 12 months. This review has been conducted under Project Orbis which is an initiative of the FDA Oncology Center of Excellence.

Keytruda (Pembrolizumab) | Lung CancerDr. Gregory Lubiniecki, vice president, oncology global clinical development, Merck Research Laboratories, said in a press release, “Six years ago, Keytruda was the first anti-PD-1 therapy approved for the first-line treatment of metastatic non-small cell lung cancer and has changed the way metastatic disease is treated. Today’s approval marks the fifth indication for Keytruda in non-small cell lung cancer and the first indication for Keytruda in patients with resected stage IB (T2a ≥4 cm), II, or IIIA disease following adjuvant chemotherapy.” “This is an important milestone as we continue our efforts to pursue meaningful advances for patients with non-small cell lung cancer,” he added.

The information shared in this blog is for educational purposes only and is not a substitute for medical advice. Please consult your healthcare professional for any medical needs.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,322)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d